Business Context and Reporting Period
This Form 8-K Current Report, dated June 25, 2026, is filed by BIO-TECHNE Corporation (NASDAQ: TECH). The filing announces the execution of an Agreement and Plan of Merger between Bio-Techne, Merck KGaA, Darmstadt, Germany, and EMD Holdings NewCo, Inc., a wholly-owned subsidiary of Merck KGaA.
Key Financial Metrics
This filing is a disclosure of a material event (Regulation FD) and does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. Investors should refer to Bio-Techne's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, for historical financial data.
Material Changes
The primary material change disclosed is the initiation of a proposed acquisition of Bio-Techne by Merck KGaA. No other operational or financial changes are detailed in this specific document.
Guidance, Outlook, Risks, and Contingencies
Outlook and Forward-Looking Statements: The filing includes extensive cautionary statements regarding forward-looking information. Actual results may differ materially from projections due to various risks.
Key Risks and Contingencies:
- Transaction Completion: Risks regarding Merck KGaA's ability to successfully complete the acquisition or realize anticipated benefits.
- Integration Challenges: Potential difficulties, delays, or higher costs in integrating Bio-Techne's operations into Merck KGaA.
- Approvals: Failure to obtain shareholder approval or satisfy other transaction conditions.
- Competitive Bids: Possibility of competing offers or acquisition proposals.
- Operational Disruption: Risks of customer loss, increased operating costs, and disruption to management attention.
- Employee Retention: Uncertainty regarding the retention of key employees.
- Market Impact: Potential adverse effects on the market price of Bio-Techne's common stock if the transaction is not consummated.
- Legal and Regulatory: Risks related to legal proceedings, intellectual property claims, and delays in obtaining required approvals.
- Financial Impact: Risks associated with indebtedness incurred by Merck KGaA and fluctuations in non-U.S. currencies.
Shareholder Action: Bio-Techne intends to file a proxy statement on Schedule 14A. Shareholders are urged to read all relevant documents when available.
Important Facts for Investor Verification
- Verify the terms of the Agreement and Plan of Merger in the attached Joint Press Release (Exhibit 99.1) and the upcoming Proxy Statement.
- Confirm the timeline for shareholder approval and regulatory clearances.
- Review Bio-Techne's most recent Form 10-K (fiscal year ended June 30, 2025) for baseline financial health prior to the transaction.
- Monitor for any competing offers or changes in the transaction structure.
- Assess the potential impact on stock price volatility during the pendency of the transaction.